FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 646 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Dunkin’ Customer Surprises Homeless Employee With Fully Furnished Home December 15, 2021 FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection January 14, 2026 NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable... April 3, 2026 Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate... December 11, 2025 Load more HOT NEWS Program Helps Medically Underserved, Minority Cancer Survivors Be More Active Patient Guide in Colorectal Cancer Now Available in Bulgarian Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations
